The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritisS0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease
Hussain N, Proctor D, Ruggiero E, Al-Bawardy B. S0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2020, 115: s356-s356. DOI: 10.14309/01.ajg.0000704884.71749.ca.Peer-Reviewed Original Research